Buscar
10X Genomics Inc
TXGAñadir a la lista de seguimiento
35.730USD
+1.130+3.27%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
4.54BCap. mercado
PérdidaP/E TTM
Más Datos de 10X Genomics Inc Compañía
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Información de 10X Genomics Inc
Símbolo de cotizaciónTXG
Nombre de la empresa10X Genomics Inc
Fecha de salida a bolsaSep 12, 2019
Director ejecutivoSaxonov (Serge Wilson)
Número de empleados1306
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 12
Dirección6230 Stoneridge Mall Road
CiudadPLEASANTON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94588
Teléfono19254017300
Sitio Webhttps://www.10xgenomics.com/
Símbolo de cotizaciónTXG
Fecha de salida a bolsaSep 12, 2019
Director ejecutivoSaxonov (Serge Wilson)
Ejecutivos de 10X Genomics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.13M
-2.55%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
378.44K
+2.33%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+22.53%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
105.23K
-11.02%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
68.28K
+12.93%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
37.45K
+23.58%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
37.45K
+23.58%
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.13M
-2.55%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
378.44K
+2.33%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+22.53%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
105.23K
-11.02%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
68.28K
+12.93%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
37.45K
+23.58%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de 10X Genomics Inc?
Los cinco principales accionistas de 10X Genomics Inc son: Mr. Serge Wilson Saxonov, Ph.D.
¿Cuántas instituciones poseen acciones de 10X Genomics Inc (TXG)?
A fecha de 2026Q1, 726 instituciones poseen acciones de 10X Genomics Inc, con un valor de mercado combinado de aproximadamente 140.84M, lo que representa el 118.45% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2946322.00.
¿Cuál es la mayor fuente de ganancias de 10X Genomics Inc?
El 2026Q1, el segmento empresarial Consumables generó la ganancia más alta para 10X Genomics Inc, ascendiendo a 507.18M y representando el 78.90% de la ganancia total.
